3-(Bromoacetyl) coumarin is a potential therapeutic agent against neonatal sepsis-associated Pseudomonas extremorientalis

• Published in: Archives of microbiology 2023-09, Vol.205 (9), p.312-312, Article 312
• Main Authors: Banerjee, Shukla, Bajire, Sukesh Kumar, Mithun, H. K., Shastry, Rajesh P.
• Format: Article
• Language: English
• Subjects: Bacteria; Bacterial diseases; Bacterial infections; Biochemistry; biofilm; Biofilms; Biomedical and Life Sciences; Biotechnology; Cell Biology; Ciprofloxacin; Coumarin; Ecology; Elastase; Exopolysaccharides; Gram-negative bacteria; In vivo methods and tests; Life Sciences; mechanism of action; Microbial Ecology; Microbiology; Neonates; Original Paper; Pathogenicity; Pathogens; Pharmacology; Pseudomonas; Pseudomonas extremorientalis; Sepsis; siderophores; Strains (organisms); therapeutics; Virulence; Virulence factors
• ISSN: 0302-8933; 1432-072X
• DOI: 10.1007/s00203-023-03653-2

Neonatal sepsis is a severe bacterial infection that can lead to life-threatening complications in newborns. Pseudomonas extremorientalis is a Gram-negative bacterium and these Gram-negative organisms have been identified as a major cause of neonatal sepsis. The virulence factors produced by this bacterium play a crucial role in its pathogenicity. Therefore, targeting these virulence factors could be a potential strategy to treat neonatal sepsis caused by P. extremorientalis . In this study, we investigated the efficacy of 3-(bromoacetyl) coumarin (3-BC) in reducing the virulence factors of P. extremorientalis strains isolated from neonatal sepsis. Our results showed that 3-BC effectively reduced the production of various virulence factors, including protease, elastase, siderophore, and exopolysaccharide in these strains. Furthermore, at a concentration of 125 µg/ml, 3-BC also inhibited the biofilm formation ability of these strains in combination with ciprofloxacin. It was discovered that 3-BC was functionally effective in protecting C. elegans against bacterial infection. Moreover, the in vitro and in vivo outcomes were strongly correlated with docking studies of various activator proteins. Overall, our findings suggest that 3-BC could be a potential therapeutic agent for the treatment of neonatal sepsis caused by P. extremorientalis . Further studies are needed to explore the mechanism of action of 3-BC and its potential use in clinical settings.